Associated Papers
Comparative analysis of RNA expression in a single institution cohort of pediatric cancer patients.
Vasquez YA et al.
Npj Precision Oncology, 2025
Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review).
Hao W et al.
International Journal of Molecular Medicine, 2025
Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database.
Waliany S et al.
Cancer Medicine, 2024
Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients.
Hong L et al.
Npj Precision Oncology, 2024
HER2 mutations in advanced cervical neuroendocrine carcinoma: implications for trastuzumab deruxtecan therapy.
Chao WR et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2024
Somatic mutations in 3929 HPV positive cervical cells associated with infection outcome and HPV type.
Pinheiro M et al.
Nature Communications, 2024
Beyond tobacco: genomic disparities in lung cancer between smokers and never-smokers.
Garrido J et al.
Bmc Cancer, 2024
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study.
Randon G et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Genomic profiling of colorectal cancer in large-scale Chinese patients: amplification and somatic mutations in ERBB2.
Liu Y et al.
Oncology Research, 2024
Next generation sequencing and genomic mapping: towards precision molecular diagnosis of lung cancer in Morocco.
Morjani O et al.
The Pan African Medical Journal, 2024
Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations.
Tian H et al.
The Oncologist, 2023
ERBB2 mutation landscape in non-small cell lung cancer patients in Northeast China.
Li H et al.
Tumori, 2023
Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects.
Ishiyama N et al.
Cancer Research, 2023
The landscape of actionable genomic alterations in lung adenocarcinomas in India.
Sharma R et al.
Frontiers in Genetics, 2023
Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer.
Lyu D et al.
Chinese Journal of Cancer Research = Chung-kuo Yen Cheng Yen Chiu, 2022
Ensemble of nucleic acid absolute quantitation modules for copy number variation detection and RNA profiling.
Wu LR et al.
Nature Communications, 2022
Germline Variants in Cancer Genes from Young Breast Cancer Mexican Patients.
Gómez-Flores-Ramos L et al.
Cancers, 2022
Molecular Pathology of Breast Tumors: Diagnostic and Actionable Genetic Alterations.
Ross DS et al.
Surgical Pathology Clinics, 2021
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.
Bakouny Z et al.
Nature Communications, 2021
Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
Sivapiragasam A et al.
Cancer Medicine, 2021
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Hescheler DA et al.
Frontiers in Endocrinology, 2021
Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Kurozumi S et al.
Breast Cancer Research : Bcr, 2020
KIT/PDGFRA/KDR amplification defines a novel molecular subtype of adenoid cystic carcinoma patients who may benefit from treatment with tyrosine kinase inhibitors.
Hou H et al.
Translational Cancer Research, 2020
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer.
Yi Z et al.
Npj Breast Cancer, 2020
Computational algorithms for in silico profiling of activating mutations in cancer.
Jordan EJ et al.
Cellular and Molecular Life Sciences : Cmls, 2019
Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms.
Lima ZS et al.
Journal of Hematology & Oncology, 2019
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG et al.
Breast Cancer Research : Bcr, 2019
Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy.
Jin J et al.
Frontiers in Oncology, 2019
Response to Afatinib in a Patient with Non-Small Cell Lung Cancer Harboring HER2 R896G Mutation: A Case Report.
Lin L et al.
Oncotargets and Therapy, 2019
Integrative omics analyses broaden treatment targets in human cancer.
Sengupta S et al.
Genome Medicine, 2018
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
Ross JS et al.
Cancer, 2018
Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature.
Petrelli F et al.
Breast Cancer Research and Treatment, 2017
TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.
Gray PN et al.
Oncotarget, 2016
Combination of In Silico Analysis and In Vitro Assay to Investigate Drug Response to Human Epidermal Growth Factor Receptor 2 Mutations in Lung Cancer.
Yu X et al.
Molecular Informatics, 2016
Analysis of different HER-2 mutations in breast cancer progression and drug resistance.
Sun Z et al.
Journal of Cellular and Molecular Medicine, 2015
HER2 missense mutations have distinct effects on oncogenic signaling and migration.
Zabransky DJ et al.
Proceedings of the National Academy of Sciences of the United States of America, 2015
Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia.
Mansour MR et al.
British Journal of Haematology, 2015
Structure-functional prediction and analysis of cancer mutation effects in protein kinases.
Dixit A et al.
Computational and Mathematical Methods in Medicine, 2014
Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations.
Ross JS et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
Activating mutations and senescence secretome: new insights into HER2 activation, drug sensitivity and metastatic progression.
Acharyya S
Breast Cancer Research : Bcr, 2013
Activating HER2 mutations in HER2 gene amplification negative breast cancer.
Bose R et al.
Cancer Discovery, 2013
Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.
Lee JW et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2006